Description

BSE lists 8,40,000 new equity shares of Sampre Nutritions Ltd. issued on preferential basis pursuant to warrant conversion, effective November 11, 2025.

Summary

BSE has listed 8,40,000 new equity shares of Sampre Nutritions Ltd. (Scrip Code: 530617) issued on a preferential basis to promoters and non-promoters pursuant to warrant conversion. The shares will be available for trading from Tuesday, November 11, 2025, and rank pari-passu with existing equity shares.

Key Points

  • Total shares listed: 8,40,000 equity shares of Rs. 10/- each
  • Issue price: Rs. 60.50/- (including premium of Rs. 50.50/-)
  • ISIN: INE375C01014
  • Distribution numbers: 21006856 to 21846855
  • Shares issued to promoters and non-promoters on preferential basis
  • Issued pursuant to conversion of warrants
  • Shares rank pari-passu with existing equity shares

Regulatory Changes

No regulatory changes introduced by this circular.

Compliance Requirements

Trading members must note the listing of new securities and the applicable lock-in periods for trading purposes.

Important Dates

  • Allotment Date (First Tranche): September 12, 2025 (5,50,000 shares)
  • Allotment Date (Second Tranche): September 25, 2025 (2,90,000 shares)
  • Trading Commencement: November 11, 2025
  • Lock-in Expiry:
    • 5,00,000 shares (Dist. Nos. 21006856-21506855): August 25, 2027
    • 50,000 shares (Dist. Nos. 21506856-21556855): August 25, 2026
    • 2,90,000 shares (Dist. Nos. 21556856-21846855): August 25, 2027

Impact Assessment

This is a routine corporate action with limited market impact. The preferential allotment increases the equity base of Sampre Nutritions Ltd. by 8,40,000 shares. The lock-in periods ranging from approximately 9 months to 2 years and 9 months ensure that most shares cannot be immediately traded, limiting short-term supply impact. The allotment to both promoters and non-promoters may affect shareholding patterns as per disclosure requirements.

Impact Justification

Routine listing of preferential shares from warrant conversion for a small-cap company with minimal market-wide impact